TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Tanta University · Heidelberg University · +2 more institutions
Abstract
Liver fibrosis is an advanced liver disease condition, which could progress to cirrhosis and hepatocellular carcinoma. To date, there is no direct approved antifibrotic therapy, and current treatment is mainly the removal of the causative factor. Transforming growth factor (TGF)-β is a master profibrogenic cytokine and a promising target to treat fibrosis. However, TGF-β has broad biological functions and its inhibition induces non-desirable side effects, which override therapeutic benefits. Therefore, understanding the pleiotropic effects of TGF-β and its upstream and downstream regulatory mechanisms will help to design better TGF-β based therapeutics. Here, we summarize recent discoveries and milestones on…
Citation impact
- FWCI
- 41.08
- Percentile
- 100%
- References
- 287
Authors
4- BDBedair Dewidar
Tanta University, Heidelberg University, University Hospital Heidelberg, University Medical Centre Mannheim
- CMChristoph Meyer
Heidelberg University, University Hospital Heidelberg, University Medical Centre Mannheim
- SDSteven Dooley
Heidelberg University, University Hospital Heidelberg, University Medical Centre Mannheim
- ANand Nadja Meindl-BeinkerCorresponding
Heidelberg University, University Hospital Heidelberg, University Medical Centre Mannheim
Topics & keywords
- Hepatic stellate cell
- Cirrhosis
- Transforming growth factor
- Cancer research
- Epithelial–mesenchymal transition
- Mesenchymal stem cell
- Transforming growth factor beta
- Liver disease